| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 12 Nov 2026 | S-3ASR |
| 12 Nov 2026 | 10-Q |
| 12 Nov 2026 |
8-K: Results of Operations and Financial Condition
LONDON and NEW YORK, November 12, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced financial and operational results for the third quarter e... |
| 20 Oct 2026 |
Form 4: Giroux Richard, CFO & COO
Sold 56,000 shares ($557K) |
| 20 Oct 2026 | 144 |
| 06 Oct 2026 |
Form 4: Naylor Stuart, CHIEF SCI OFCR, OPHTHALMOLOGY
Sold 27,659 shares ($294K) |
| 06 Oct 2026 | 144 |
| 24 Sep 2026 |
Form 4: Sebulsky Alan, Director
Granted 100,000 Restricted Share Units |
| 24 Sep 2026 |
Form 3: Sebulsky Alan, Director
Holds 34,500 shares of Ordinary Shares |
| 23 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
LONDON and NEW YORK, September 23, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced the appointment of Alan M. Sebulsky to its Board of Dire... |
| 18 Aug 2026 |
Form 4: Forbes Alexandria, Director
Sold 62,000 shares ($859K) |
| 18 Aug 2026 | 144 |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 13 Aug 2026 | S-8 |
| 13 Aug 2026 | 10-Q |
| 13 Aug 2026 |
8-K: Results of Operations and Financial Condition
Received FDA Breakthrough Therapy Designation for AAV2-hAQP1 and reported positive three-year data from Phase 1 AQUAx clinical trial evaluating AAV2-hAQP1 for the treatment of moderate to severe grade 2/3 radiation-induced xerostomia |
| 21 Jul 2026 |
Form 4: Giroux Richard, CFO & COO
Sold 56,000 shares ($701K) |
| 21 Jul 2026 | 144 |
| 07 Jul 2026 |
Form 4: Naylor Stuart, CHIEF SCI OFCR, OPHTHALMOLOGY
Sold 27,659 shares ($409K) |
Loading...